[Frontiers in Bioscience 2, e12-20, April 1, 1997]
Reprint
PubMed
CAVEAT LECTOR




Table of Conents
 Previous Section   Next Section

VENOUS THROMBOEMBOLISM AND CANCER: A TWO-WAY CLINICAL ASSOCIATION

Paolo Prandoni, MD, PhD and Andrea Piccioli, MD

Institute of Medical Semeiotics, University of Padua, Via Ospedale Civile, 105, 35128 - PADOVA, (Italy)

Received 3/28/97; Accepted 3/31/97; On-line 4/15/97

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Pathogenesis
3.1. Hypercoagulability
3.2. Vessel wall damage
3.3. Venous stasis
4. Clinical implications
4.1. Search for occult malignancies in patients with ideopathic VTE
4.2. Primary prophylaxis of VTE
4.2.1. Surgical interventions
4.2.2. Chemotherapy
4.2.3. Central venous catheters
4.3. Treatment and secondary prophylaxis of VTE
4.3.1. Duration and intensity of anticoagulation
4.3.2. Recurrence of venous thromboembolism during oral anticoagulation
4.3.3. Hemorrrhagic risk related to anticoagulation
4.4. Reduction of mortality
5. References
6. Entire manuscript

Key words: Thrombosis, venous thromboembolism, cancer, anticoagulation, heparin, low-molecular-weight heparin, warfarin, chemotherapy